NATALEE: Ribociclib Plus Endocrine Therapy in Early HR-Positive, HER2-Negative Breast Cancer

Primary endpoint (iDFS, ITT): 90.4% vs 87.1% at 3 years — HR 0.75 (95% CI, 0.62 to 0.91; P=0.003) Key secondary (DDFS): 90.8% vs 88.6% at 3 years — HR 0.74 (95% CI, 0.60 to 0.91) Key secondary (RFS): 91.7% vs 88.6% at 3 years — HR 0.72 (95% CI, 0.58 to 0.88) Key secondary (OS): HR 0.76 (95% CI, 0.54 to 1.07) — immature Safety signal: Grade 3 or higher neutropenia in 43.8% with ribociclib–NSAI vs 0.8% with NSAI alone; liver-related AEs grade 3 or 4 in 8.3% vs 1.5%

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

NATALEE demonstrated that adding ribociclib at a reduced dose to adjuvant endocrine therapy with a nonsteroidal aromatase inhibitor significantly improved invasive disease-free survival in patients with stage II or III hormone receptor–positive, HER2-negative early breast cancer. The benefit was consistent across patients with both stage II and stage III disease, extending the population of patients who may benefit from adjuvant CDK4/6 inhibition beyond the high-risk, node-positive patients studied in monarchE.

This trial reshaped the adjuvant treatment landscape for HR-positive, HER2-negative breast cancer by establishing ribociclib as a second CDK4/6 inhibitor with demonstrated efficacy in the adjuvant setting. Critically, NATALEE enrolled a broader risk population than monarchE — including node-negative patients with high-risk features and stage IIA disease — and used a lower dose of ribociclib administered continuously for three years. As of 2026, adjuvant ribociclib plus endocrine therapy is an NCCN-recommended option for eligible patients with stage II or III HR-positive, HER2-negative breast cancer.

The key practical concerns are the high rates of neutropenia, hepatotoxicity, and the requirement for ECG monitoring due to QT-interval prolongation. Nearly one in five patients discontinued ribociclib due to adverse events, with most discontinuations occurring early (median time to discontinuation of four months). Liver-related events were the most common cause of treatment discontinuation. Clinicians must weigh the absolute survival benefit against the treatment burden and toxicity profile in shared decision-making, particularly for patients at intermediate risk.

Trial Overview

Study Design

• Trial name and registration: NATALEE (NCT03701334)
• Design: Phase 3, randomized, open-label, international; prespecified interim analysis
• Randomization: 1:1, stratified by anatomical stage (II or III), menopausal status (premenopausal women and men or postmenopausal women), previous adjuvant or neoadjuvant chemotherapy (yes or no), and geographic location (North America, Western Europe, Oceania, or rest of the world)
• Setting: Stage II or III HR-positive, HER2-negative early breast cancer (adjuvant)
• Enrollment period and sites: January 10, 2019, to April 20, 2021

Mechanism of Action

Ribociclib is a selective, oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking CDK4/6, ribociclib prevents phosphorylation of the retinoblastoma protein, thereby arresting the cell cycle at the G1/S transition and inhibiting tumor cell proliferation in hormone receptor–positive breast cancer cells that rely on CDK4/6–cyclin D1 signaling [2].

Patient Population

• Key eligibility: Men or premenopausal or postmenopausal women ≥18 years; histologically confirmed HR-positive, HER2-negative early breast cancer by local assessment; stage II or III (AJCC 8th Edition). All patients with stage III or IIB disease were eligible irrespective of nodal status. Stage IIA patients were eligible if they had at least one lymph node involved, or if node-negative with a grade 2 tumor and Ki-67 ≥20% or high genomic risk, or if node-negative with grade 3 tumors. ECOG 0 or 1.
• Biomarker selection: HR-positive, HER2-negative by local assessment.
• Sample size flow: 5101 randomized (2549 ribociclib–NSAI, 2552 NSAI alone) → safety population 4968 (2524 ribociclib–NSAI, 2444 NSAI alone). Number screened was not reported in this publication.

Baseline Characteristics

Race data were reported for all patients combined: 73.4% White, 13.2% Asian, 1.7% Black.

Treatment Protocol

Experimental Arm: Ribociclib+NSAI (n=2549 randomized; safety population n=2524)

Ribociclib plus a nonsteroidal aromatase inhibitor (letrozole or anastrozole). Premenopausal women and men also received goserelin.

• Dose and schedule: Ribociclib 400 mg orally once daily for 21 consecutive days, followed by 7 days off (28-day cycle) for 36 months; plus letrozole 2.5 mg orally once daily or anastrozole 1 mg orally once daily on a continuous schedule for ≥60 months. Goserelin 3.6 mg subcutaneously every 28 days for premenopausal women and men.
• Treatment duration: Ribociclib for 36 months; NSAI for ≥60 months
• Median treatment duration: 30 months (trial treatment overall); 27 months (ribociclib alone)
• Median relative dose intensity: Not reported in this publication

At data cutoff, 515 patients (20.2%) had completed the planned 3 years of ribociclib, 1147 patients (45.0%) were continuing to receive ribociclib, and 1449 (56.8%) had completed at least 2 years of ribociclib plus NSAI. Overall, 1984 patients (77.8%) were still on treatment in this group.

Control Arm: NSAI Alone (n=2552 randomized; safety population n=2444)

Nonsteroidal aromatase inhibitor alone (letrozole or anastrozole). Premenopausal women and men also received goserelin.

• Dose and schedule: Letrozole 2.5 mg orally once daily or anastrozole 1 mg orally once daily on a continuous schedule for ≥60 months. Goserelin 3.6 mg subcutaneously every 28 days for premenopausal women and men.
• Treatment duration: NSAI for ≥60 months
• Median treatment duration: 30 months

At data cutoff, 1826 patients (71.6%) were still on treatment in this group.

Efficacy Outcomes

Primary Endpoint: Invasive Disease–Free Survival (iDFS)

Definition: Defined according to standardized definitions for efficacy end points (STEEP) criteria, version 1.0, as assessed by the investigator.

Analysis population: Intention-to-treat (all 5101 randomized patients)

Statistical method: Stratified log-rank test; hazard ratios estimated by stratified Cox proportional-hazards model

Median follow-up: 27.7 months (for iDFS, from randomization to last completed recurrence assessment); 34 months (from randomization to data cutoff; minimum 21 months)

Alpha allocation: 0.025 one-sided, with Lan–DeMets (O'Brien–Fleming) stopping boundary. Two-sided P-value threshold at this interim: 0.0256.

Ribociclib+NSAI: 3-year iDFS 90.4% (confidence interval not reported); 189 events in 2549 patients (7.4%) NSAI Alone: 3-year iDFS 87.1% (confidence interval not reported); 237 events in 2552 patients (9.3%) Comparison: HR 0.75 (95% CI, 0.62 to 0.91; two-sided P=0.003)

The two-sided P value of 0.003 crossed the prespecified stopping boundary (P-value threshold of 0.0256). This analysis was performed after 426 of 500 expected events had occurred.

Key Secondary Endpoints

Distant Disease–Free Survival (DDFS)

Analysis population: Intention-to-treat

Formally tested: Yes

Ribociclib+NSAI: 3-year DDFS 90.8%; 167 events NSAI Alone: 3-year DDFS 88.6%; 212 events Comparison: HR 0.74 (95% CI, 0.60 to 0.91); p-value not reported

Recurrence-Free Survival (RFS)

Analysis population: Intention-to-treat

Formally tested: Yes

Ribociclib+NSAI: 3-year RFS 91.7%; 159 events NSAI Alone: 3-year RFS 88.6%; 207 events Comparison: HR 0.72 (95% CI, 0.58 to 0.88); p-value not reported

Overall Survival (OS)

Analysis population: Intention-to-treat

Formally tested: Not reported in this publication

OS data were described as currently immature at median follow-up of 30 months for overall survival.

Ribociclib+NSAI: 61 of 2549 patients (2.4%) had died NSAI Alone: 73 of 2552 patients (2.9%) had died Comparison: HR 0.76 (95% CI, 0.54 to 1.07); p-value not reported

The confidence interval for OS crosses 1.0, consistent with the immaturity of these data.

Exploratory Endpoints

Distant Recurrence–Free Survival (DRFS)

Analysis population: Intention-to-treat

The exploratory endpoint of distant recurrence–free survival was also improved with ribociclib plus an NSAI as compared with an NSAI alone.

Comparison: HR 0.72 (95% CI, 0.58 to 0.89); p-value not reported

Distant recurrences occurred in 120 patients (4.7%) in the ribociclib–NSAI group and 170 patients (6.7%) in the NSAI group.

Safety

Safety Population

Safety was assessed in 2524 patients in the ribociclib–NSAI group and 2444 patients in the NSAI group.

Safety Summary

Discontinuation due to AE in the NSAI alone group was not reported in this publication. Most discontinuations of ribociclib occurred early during treatment, with a median time to ribociclib discontinuation of 4 months. The most common adverse events leading to discontinuation of any trial treatment were liver-related events (8.9% ribociclib–NSAI vs 0.1% NSAI alone) and arthralgia (1.3% vs 1.9%).

Grade ≥3 Adverse Events of Clinical Significance

The most frequent grade 3 or higher event was neutropenia, occurring in 43.8% of patients in the ribociclib–NSAI group and 0.8% in the NSAI group.

Adverse Events of Special Interest

⚠️ Liver-Related Adverse Events: Critical Safety Signal

• Any grade: 25.4% (ribociclib–NSAI) vs 10.6% (NSAI alone)
• Grade 3 or 4: 209 (8.3%) vs 37 (1.5%)
• Hy's law cases: 8 (0.3%) vs 1 (<0.1%)
• Management: Liver-related events were the most common cause of treatment discontinuation (8.9% vs 0.1%). Dose interruption and dose reduction per protocol are essential components of hepatotoxicity management.
• Clinical implication: Hepatic function monitoring (AST, ALT, bilirubin) must be performed before initiation and regularly during treatment. The occurrence of Hy's law cases — albeit rare — underscores the potential for severe drug-induced liver injury requiring immediate discontinuation.

⚠️ QT-Interval Prolongation: Critical Safety Signal

• Any grade: 5.2% (ribociclib–NSAI) vs 1.2% (NSAI alone)
• New QTcF >500 msec: 3 of 2505 (0.1%) vs 1 of 2380 (<0.1%)
• QTcF increase from baseline >60 msec: 19 of 2505 (0.8%) vs 2 of 2380 (0.1%)
• Management: ECG monitoring is required before initiation and during treatment [2]. Patients with clinically significant, uncontrolled heart disease or cardiac repolarization abnormalities were excluded from the trial.
• Clinical implication: Though the incidence of clinically dangerous QT prolongation (>500 msec) was low, ECG monitoring adds logistical burden. Concomitant medications that prolong the QT interval should be avoided or used with caution.

Deaths

• Total deaths (safety population): 60 (2.4%) in the ribociclib–NSAI group and 74 (3.0%) in the NSAI group
• Treatment-related deaths: 0 in both groups. No deaths were considered to be related to the trial treatment.
• Deaths without disease progression or recurrence: 19 patients in the ribociclib–NSAI group and 13 patients in the NSAI group
• Deaths during treatment or within 30 days after last dose: 17 (0.7%) in the ribociclib–NSAI group and 9 (0.4%) in the NSAI group. Among these, 10 (0.4%) occurred within 30 days after the last dose of ribociclib.

Note: Death counts in the safety population (60 vs 74) differ slightly from the ITT population (61 vs 73) used for the OS endpoint analysis.

Subgroup Analyses

Subgroup analyses for the primary endpoint of iDFS were reported for stage II vs stage III disease.

At 3 years, the absolute invasive disease–free survival benefit with ribociclib plus NSAI was 3.0 percentage points among patients with stage II disease and 3.2 percentage points among those with stage III disease. Individual hazard ratios and confidence intervals by subgroup were not reported in the main text (detailed forest plot was in supplementary Figure S4, which was not available for extraction).

These subgroup analyses were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

NATALEE and monarchE are the two trials that have established CDK4/6 inhibitors as effective adjuvant therapy in HR-positive, HER2-negative early breast cancer, while PALLAS (palbociclib) did not demonstrate an iDFS benefit. The key differences between NATALEE and monarchE are clinically significant and affect patient selection:

• Population breadth: NATALEE enrolled a broader risk population including stage IIA patients with specific high-risk node-negative features, whereas monarchE was restricted to patients with ≥4 positive axillary lymph nodes, or 1–3 positive nodes with at least one additional high-risk feature (grade 3, tumor ≥5 cm, or high Ki-67).
• CDK4/6 inhibitor and dose: NATALEE used ribociclib at a reduced dose of 400 mg daily (compared with 600 mg in the metastatic setting), while monarchE used abemaciclib at 150 mg twice daily — the standard metastatic dose.
• Treatment duration: Ribociclib was given for 36 months in NATALEE; abemaciclib was given for 24 months in monarchE.
• Absolute benefit magnitude: The absolute 3-year iDFS benefit in NATALEE was approximately 3.3 percentage points, while monarchE reported a larger absolute 4-year iDFS benefit of approximately 6.4 percentage points — though the higher-risk monarchE population had a higher baseline event rate.
• Toxicity profile: NATALEE's predominant toxicity is neutropenia and hepatotoxicity; monarchE's predominant toxicity with abemaciclib is diarrhea.

The failure of PALLAS with palbociclib [5] suggests that the adjuvant benefit is not a class effect across all CDK4/6 inhibitors, and drug-specific pharmacologic properties or dosing strategies may be important.

Grey Zones and Unanswered Questions

• Stage IIA node-negative patients: NATALEE included select node-negative stage IIA patients (grade 2 with Ki-67 ≥20%, high genomic risk, or grade 3), but the absolute benefit in this lower-risk subgroup is not separately reported with precision. Whether the benefit-to-risk ratio favors adding 3 years of ribociclib in patients whose baseline recurrence risk may already be modest is a critical question for clinical practice.

• Overall survival: With only 134 total deaths across both arms (HR 0.76; 95% CI, 0.54 to 1.07), the OS data are immature and do not demonstrate a statistically significant survival benefit. Given the long natural history of HR-positive breast cancer, determining whether the iDFS benefit translates into a meaningful OS advantage will require years of additional follow-up.

• Optimal duration of CDK4/6 inhibitor therapy: NATALEE administered ribociclib for 36 months, while monarchE used abemaciclib for 24 months. Whether shorter durations of ribociclib (e.g., 24 months) would preserve the efficacy benefit while reducing toxicity burden is unknown.

• Genomic risk scores and patient selection: The eligibility criteria for node-negative stage IIA patients referenced "high genomic risk," but the publication does not report outcomes stratified by genomic assay results (Oncotype DX, MammaPrint, etc.). Whether patients with favorable genomic profiles should be spared CDK4/6 inhibitor therapy — even if they have stage II disease by anatomic criteria — is unanswered.

• Choice between ribociclib and abemaciclib in the adjuvant setting: No head-to-head comparison exists. The different toxicity profiles (neutropenia/hepatotoxicity for ribociclib vs diarrhea for abemaciclib), dosing schedules, and treatment durations complicate the choice. Patient comorbidities, tolerability preferences, and risk level may guide selection, but evidence-based criteria for choosing one over the other are lacking.

Clinical Implications

Rationale and Clinical Context

HR-positive, HER2-negative breast cancer accounts for approximately two-thirds of all breast cancers. Despite the efficacy of adjuvant endocrine therapy, late recurrences — occurring 5, 10, or even 20 years after diagnosis — remain a persistent challenge, particularly in patients with anatomically higher-stage disease. Before NATALEE and monarchE, the adjuvant treatment algorithm for HR-positive early breast cancer consisted of endocrine therapy alone (with or without prior chemotherapy), and CDK4/6 inhibitors were established only in the metastatic setting. NATALEE tested whether adding ribociclib at a reduced dose of 400 mg daily for 3 years to standard adjuvant NSAI therapy could reduce recurrence in a broad population of stage II–III patients.

Monitoring and Long-Term Follow-Up

Based on the safety profile observed in NATALEE, patients treated with adjuvant ribociclib require:

• Complete blood count: Before initiation and at the start of each cycle for the first 2 cycles, then as clinically indicated. Neutropenia (grade 3: 41.8%, grade 4: 2.1%) is the dominant hematologic toxicity but was manageable with dose modifications.
• Hepatic function (AST, ALT, bilirubin): Before initiation and every 2 weeks for the first 2 cycles, then monthly for the next 4 cycles, then as clinically indicated [2]. Grade 3 or 4 liver-related events occurred in 8.3% of patients.
• ECG monitoring: Before initiation, at approximately day 14 of cycle 1, and at the beginning of cycle 2. QT-interval prolongation of any grade was observed in 5.2% of patients [2].
• Long-term follow-up: Given the 34-month median follow-up in this analysis, long-term data on late recurrences, OS, and delayed toxicities are pending. The natural history of HR-positive breast cancer means that meaningful survival data will require follow-up well beyond 5 years.

Unanswered Questions

The two most practice-relevant open questions from this trial are (1) whether the iDFS benefit will translate into an overall survival advantage, which is particularly important given that no treatment-related deaths were observed but 19 patients in the ribociclib arm died without disease progression or recurrence (vs 13 in the NSAI arm), and (2) how to select between adjuvant ribociclib and abemaciclib for individual patients — a decision currently guided by toxicity profiles, patient preferences, and available risk stratification data rather than comparative efficacy evidence.

Regulatory and Guideline Status

Regulatory

• FDA: Ribociclib (Kisqali) received FDA approval on September 15, 2023, for adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence, in combination with an aromatase inhibitor (with or without an LHRH agonist), based on the NATALEE trial results. The approved adjuvant dose is 400 mg daily (21 days on, 7 days off). Regulatory status should be verified with current FDA/EMA labeling.
• EMA: Approved for the adjuvant indication. Regulatory status should be verified with current EMA labeling.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: Ribociclib plus endocrine therapy is a recommended option in the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer for adjuvant treatment of stage II–III HR-positive, HER2-negative early breast cancer meeting appropriate risk criteria [3].

Companion Diagnostics

HR-positive, HER2-negative status was determined by local assessment. No specific companion diagnostic test is required for ribociclib use in this indication. Standard hormone receptor and HER2 testing per institutional protocols is required for patient selection.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Slamon DJ, Stroyakovskiy D, Yardley DA, et al. Ribociclib and Endocrine Therapy as Adjuvant Treatment in Patients with HR+/HER2− Early Breast Cancer: NATALEE. N Engl J Med. 2024. doi:10.1056/NEJMoa2305488
2. Kisqali (ribociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514
5. Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40(3):282-293. doi:10.1200/JCO.21.02554